Research location
Wroclaw
Lower Silesian Voivodeship, Poland
Advertisement
Research activity in Wroclaw
Lower Silesian Voivodeship, PolandCureCurrent currently publishes aggregate city-level research activity for this location: 112 trials and 128 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Wroclaw
112 linked trials · page 2 of 3A Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719 · 2021-09-15 · 1 site observation
COMPLETED
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatNCT04981717 · 2021-07-30 · 2 site observations
TERMINATED
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).NCT04895722 · 2021-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 InflammationNCT04773678 · 2021-05-11 · 1 site observation
COMPLETED
Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal GelNCT04500106 · 2021-04-22 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 · 2021-01-22 · 1 site observation
COMPLETED
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)NCT04662710 · 2020-12-30 · 1 site observation
COMPLETED
Global Prevalence of ATTR-CM in Participants With HFpEFNCT04424914 · 2020-12-30 · 1 site observation
TERMINATED
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04701983 · 2020-12-16 · 1 site observation
COMPLETED
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting MethodNCT04601545 · 2020-10-23 · 1 site observation
COMPLETED
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498 · 2020-10-01 · 1 site observation
TERMINATED
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic ShockNCT04325035 · 2020-09-28 · 1 site observation
COMPLETED
MSB11456 in Participants With Moderately to Severely Active Rheumatoid ArthritisNCT04512001 · 2020-08-03 · 2 site observations
COMPLETED
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 2 site observations
COMPLETED
Ketogenic Diet in Women With LipedemaNCT07530341 · 2020-02-20 · 1 site observation
COMPLETED
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)NCT04223778 · 2020-02-18 · 1 site observation
COMPLETED
Selenoprotein and Renalase Blood Levels in Patients With Hypertensive Heart Disease and Obstructive Sleep ApneaNCT05040516 · 2020-01-27 · 1 site observation
UNKNOWN
Visfatin and Omentin-1 - Markers of Nutritional Status of Newborns Born to Diabetic Mothers.NCT04937348 · 2019-12-13 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisNCT04035005 · 2019-08-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)NCT03924856 · 2019-06-13 · 1 site observation
COMPLETED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation
COMPLETED
A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.NCT04057118 · 2019-03-20 · 1 site observation
COMPLETED
Transcranial Magnetic Stimulation in Patients With a Depressive Episode - RCT TrialNCT05543421 · 2019-01-01 · 1 site observation
UNKNOWN
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)NCT03725059 · 2018-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)NCT03711032 · 2018-12-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)NCT03675737 · 2018-11-08 · 2 site observations
COMPLETED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)NCT03615326 · 2018-10-05 · 2 site observations
COMPLETED
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)NCT03516981 · 2018-10-01 · 1 site observation
COMPLETED
Low-intensity Exercise in Metabolic SyndromeNCT04346836 · 2018-05-06 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)NCT03425643 · 2018-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of High Intensity Interval Training on Mechanisms of Neuroplasticity in Parkinson's Disease PatientsNCT04204551 · 2018-02-15 · 1 site observation
UNKNOWN
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)NCT03302234 · 2017-12-14 · 1 site observation
COMPLETED
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.NCT03398356 · 2017-10-20 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)NCT03221426 · 2017-10-09 · 1 site observation
COMPLETED
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)NCT03040999 · 2017-04-05 · 1 site observation
COMPLETED
Phase 3 Alogliptin Pediatric StudyNCT02856113 · 2016-10-14 · 1 site observation
COMPLETED
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to InfliximabNCT02937701 · 2016-10-10 · 1 site observation
COMPLETED
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02889796 · 2016-08-30 · 1 site observation
COMPLETED
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease DementiaNCT02783573 · 2016-07-01 · 1 site observation
TERMINATED
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to RituximabNCT02792699 · 2016-05-17 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)NCT02706951 · 2016-03-23 · 1 site observation
COMPLETED
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsNCT02706847 · 2016-03-15 · 1 site observation
COMPLETED
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT02677896 · 2016-03-09 · 1 site observation
COMPLETED
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPDNCT02371629 · 2015-06-24 · 1 site observation
COMPLETED
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot UlcersNCT02447172 · 2015-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.